PMID- 32938734
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20231213
IS  - 1098-660X (Electronic)
IS  - 0095-1137 (Print)
IS  - 0095-1137 (Linking)
VI  - 59
IP  - 1
DP  - 2020 Dec 17
TI  - Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant 
      Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution.
LID - 10.1128/JCM.01649-20 [doi]
LID - e01649-20
AB  - Antimicrobial susceptibility testing (AST) of cefiderocol poses challenges 
      because of its unique mechanism of action (i.e., requiring an iron-depleted 
      state) and due to differences in interpretative criteria established by the 
      Clinical and Laboratory Standards Institute (CLSI), U.S. Food and Drug 
      Administration (FDA), and European Committee on Antimicrobial Susceptibility 
      Testing (EUCAST). Our objective was to compare cefiderocol disk diffusion methods 
      (DD) to broth microdilution (BMD) for AST of Gram-negative bacilli (GNB). 
      Cefiderocol AST was performed on consecutive carbapenem-resistant 
      Enterobacterales (CRE; 58 isolates) and non-glucose-fermenting GNB (50 isolates) 
      by BMD (lyophilized panels; Sensititre; Thermo Fisher) and DD (30 mug; 
      research-use-only [RUO] MASTDISCS and FDA-cleared HardyDisks). Results were 
      interpreted using FDA (prior to 28 September 2020 update), EUCAST, and 
      investigational CLSI breakpoints (BPs). Categorical agreement (CA), minor errors 
      (mE), major errors (ME), and very major errors (VME) were calculated for DD 
      methods. The susceptibilities of all isolates by BMD were 72% (FDA), 75% (EUCAST) 
      and 90% (CLSI). For DD methods, EUCAST BPs demonstrated lower susceptibility at 
      65% and 66%, compared to 74% and 72% (FDA) and 87% and 89% (CLSI) by HardyDisks 
      and MASTDISCS, respectively. CA ranged from 75% to 90%, with 8 to 25% mE, 0 to 
      19% ME, and 0 to 20% VME and varied based on disk, GNB, and BPs evaluated. Both 
      DD methods performed poorly for Acinetobacter baumannii complex. There is 
      considerable variability when cefiderocol ASTs are interpreted using CLSI, FDA, 
      and EUCAST breakpoints. DD offers a convenient alternative approach to BMD 
      methods for cefiderocol AST, with the exception of A. baumannii complex isolates.
CI  - Copyright (c) 2020 American Society for Microbiology.
FAU - Morris, C Paul
AU  - Morris CP
AD  - Division of Medical Microbiology, Johns Hopkins University School of Medicine, 
      Baltimore, Maryland, USA.
AD  - National Institute of Allergy and Infectious Diseases, National Institutes of 
      Health, Bethesda, Maryland, USA.
FAU - Bergman, Yehudit
AU  - Bergman Y
AD  - Division of Medical Microbiology, Johns Hopkins University School of Medicine, 
      Baltimore, Maryland, USA.
FAU - Tekle, Tsigedera
AU  - Tekle T
AD  - Division of Medical Microbiology, Johns Hopkins University School of Medicine, 
      Baltimore, Maryland, USA.
FAU - Fissel, John A
AU  - Fissel JA
AD  - Division of Medical Microbiology, Johns Hopkins University School of Medicine, 
      Baltimore, Maryland, USA.
FAU - Tamma, Pranita D
AU  - Tamma PD
AD  - Division of Pediatric Infectious Diseases, Johns Hopkins University School of 
      Medicine, Baltimore, Maryland, USA.
FAU - Simner, Patricia J
AU  - Simner PJ
AUID- ORCID: 0000-0001-6134-151X
AD  - Division of Medical Microbiology, Johns Hopkins University School of Medicine, 
      Baltimore, Maryland, USA psimner1@jhmi.edu.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - United States
TA  - J Clin Microbiol
JT  - Journal of clinical microbiology
JID - 7505564
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cephalosporins)
SB  - IM
CIN - https://doi.org/10.1128/JCM.00966-20
CIN - https://doi.org/10.1128/JCM.00951-20
MH  - *Anti-Bacterial Agents/pharmacology
MH  - *Cephalosporins
MH  - Gram-Negative Bacteria
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - Cefiderocol
PMC - PMC7771458
OTO - NOTNLM
OT  - antimicrobial susceptibility testing
OT  - broth microdilution
OT  - cefiderocol
OT  - disk diffusion
EDAT- 2020/09/18 06:00
MHDA- 2021/06/24 06:00
PMCR- 2021/06/17
CRDT- 2020/09/17 05:38
PHST- 2020/06/26 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/17 05:38 [entrez]
PHST- 2021/06/17 00:00 [pmc-release]
AID - JCM.01649-20 [pii]
AID - 01649-20 [pii]
AID - 10.1128/JCM.01649-20 [doi]
PST - epublish
SO  - J Clin Microbiol. 2020 Dec 17;59(1):e01649-20. doi: 10.1128/JCM.01649-20. Print 
      2020 Dec 17.